ARQT
$22.21-0.70 (-3.06%)
Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases.
Recent News
Arcutis (ARQT) Announces Long-Term Phase 3 Data for ZORYVE Cream in Children
Arcutis Biotherapeutics Inc. (NASDAQ:ARQT) is one of the best growth stocks to buy right now. On March 10, Arcutis Biotherapeutics announced the publication of long-term Phase 3 data regarding ZORYVE (roflumilast) cream 0.05% for children aged 2 to 5 with mild-to-moderate atopic dermatitis. The INTEGUMENT-OLE study, which followed patients for up to 52 weeks, showed […]
Guggenheim Raises Its Price Target on Arcutis Biotherapeutics, Inc. (ARQT) to $35 and Maintains a Buy Rating
Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) is among the 10 Fastest Growing NASDAQ Stocks to Buy. On February 27, 2026, Guggenheim raised its price target on Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) to $35 from $34 and maintained a Buy rating. The firm said it remains “encouraged” by the trajectory of Zoryve and the company’s efforts to maximize its […]
A Look At Arcutis Biotherapeutics (ARQT) Valuation After New ARQ 234 Trial Milestone
Arcutis Biotherapeutics (ARQT) has just dosed the first participant in its Phase 1a/1b trial of ARQ-234, a CD200 receptor targeting fusion protein for atopic dermatitis, marking a fresh pipeline milestone. See our latest analysis for Arcutis Biotherapeutics. At a recent share price of US$24.12, Arcutis Biotherapeutics has a 1 day share price return of 2.20%, while its 90 day share price return of 22.59% and year to date share price return of 16.83% contrast with a 1 year total shareholder...
Arcutis Biotherapeutics Spotlights ZORYVE Surge, 2025 Revenue Beat and Key FDA Milestones at TD Cowen
Arcutis Biotherapeutics (NASDAQ:ARQT) executives highlighted strong recent commercial performance for ZORYVE and outlined near-term regulatory and pipeline milestones during a presentation and fireside chat at TD Cowen’s 46th Annual Healthcare Conference. Q4 performance and 2025 results Chief Execu
Did Higher 2026 Guidance and a New Shelf Offerings Plan Just Shift Arcutis' (ARQT) Investment Narrative?
In February 2026, Arcutis Biotherapeutics reported that Q4 2025 revenue rose to US$129.5 million with net income of US$17.4 million, while full-year 2025 revenue reached US$376.07 million and net loss narrowed to US$16.14 million, alongside a filing for a universal shelf registration covering equity, debt, and related securities. Management also raised its 2026 net product revenue guidance to a range of US$480 million to US$495 million, reflecting confidence in ZORYVE’s broader commercial...